{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-008469","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2022-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.948899+00:00","generated_at":"2026-06-25T22:14:41.804688+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Enanta reports Q2 net loss of $33.6M; revenue down to $18.7M on lower HCV royalties","bullets":["Net loss of $33.6M ($1.63/share) vs. loss of $22.0M ($1.09/share) last year.","Total revenue of $18.7M, down 7% YoY, all royalty from AbbVie's HCV regimen MAVYRET.","Cash and securities $322.5M; expects to fund operations for at least two years.","Expects topline data from RSVP Phase 2b study of EDP-938 in adults with RSV this quarter.","FDA Fast Track for EDP-235 (COVID-19); preliminary Phase 1 data expected this quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-008469","json":"https://secwatch.observer/filing/0000950170-22-008469.json","markdown":"https://secwatch.observer/filing/0000950170-22-008469.md","text":"https://secwatch.observer/filing/0000950170-22-008469.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000095017022008469/0000950170-22-008469-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000095017022008469/enta-20220509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:14:41.804688+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}